依托泊苷|T0132

Etoposide
33419-42-0

￥287 50mg 起订

￥430 100mg 起订

￥697 200mg 起订

上海更新日期：2024-09-14

TargetMol中国（陶术生物）

VIP12年

联系人：邵小姐

电话：021-021-33632979拨打

手机：15002134094 拨打

邮箱：marketing@targetmol.com

产品详情:

中文名称：: 依托泊苷

英文名称：: Etoposide

CAS号：: 33419-42-0

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99.95%

产品类别：: 抑制剂

货号：: T0132

Product Introduction

Bioactivity

名称	Etoposide
描述	Etoposide (VP-16-213) is a topoisomerase II inhibitor that inhibits DNA synthesis by forming a complex with topoisomerase II and DNA (IC50=60.3 μM). Etoposide has antitumor activity and induces apoptosis and autophagy.
细胞实验	After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells [5].
激酶实验	Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained [5].
动物实验	The in vivo model for nude mice HB (NMHB) has been established. Only HB cells with embryonal components are grafted and reproduced successfully in this model. Each NMHB subsequently is transplanted into 50 mice for treatment groups. Treatment is initiated when the majority of the tumors reach a volume of 50-100 mm3. The mice are stratified according to their tumor volume and randomly assigned to groups of ten animals each. The animals injected with tumor are given ifosfamide, cisplatin, doxorubicin, etoposide (10 mg/kg/day, i.v.), and carboplatin as single agents in two blocks. One group of ten animals for each original xenograft served as a control group. After initiation of treatment, the tumor growth is recorded at 5-day intervals for 25-30 days and the relative tumor volumes are calculated. Twenty-four hours before the animals are sacrificed, bromodeoxyuridine (BrdU) is injected intraperitoneally for the semiquantitative determination of proliferation activity of the tumor cells (50 μg of BrdU/g body weight) [4].
体外活性	方法：人宫颈癌细胞 HeLa 用 Etoposide (25-400 μM) 处理 24-48 h，使用 MTT 方法检测细胞活力。结果：Etoposide 抑制 Hela 细胞增殖，处理 24 h 和 48 h 的 IC50 分别为 167.3 μM 和 52.7 μM。[1] 方法：人肺腺癌细胞 A549 用 Etoposide (0.75-3 μM) 处理 4 h，使用 Flow Cytometry 方法检测细胞周期情况。结果：Etoposide 导致 G0/G1 和 S 期的 A549 细胞百分比显著降低。同时，G2/M 期的细胞显著增加。[2] 方法：小鼠胚胎成纤维细胞 MEFs 用 Etoposide (1.5-150 μM) 处理 3-18 h，使用 Western Blot 方法检测靶点蛋白表达水平。结果：150 μM的 Etoposide 在 6 h 内诱导 Caspase-3 的强烈裂解，而 1.5 或 15 μM 仅在 18 h 后激活 Caspase-3。[3]
体内活性	方法：为检测体内抗肿瘤活性，将 Etoposide (10 mg/kg) 和 Cisplatin (5-7.5 mg/kg) 腹腔注射给携带人子宫内膜腺癌肿瘤 Ishikawa 的 KSN nude 小鼠，每两天一次，持续两周。结果：作为单一药物，Etoposide 对肿瘤生长几乎没有抑制作用。Etoposide 和 Cisplatin 联合治疗显著抑制肿瘤生长。[4] 方法：为检测体内抗肿瘤活性，将 Etoposide (80 mg/kg in 0.5% methylcellulose) 灌胃给药给携带人胶质母细胞肿瘤 U87 的免疫缺陷小鼠，每天一次，持续四十天。结果：80 mg/kg Etoposide 抑制 U87 肿瘤生长，抑制率为95%。[5]
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5.89 mg/mL (10.01 mM), Working solution is recommended to be prepared and used immediately. DMSO : 60 mg/mL (101.94 mM)
关键字	P388 \| HCT116 \| p53 \| chemotherapy \| Etoposide \| Mitochondrial Autophagy \| Topoisomerase \| FBXW \| Inhibitor \| anti-cancer \| inhibit \| VP 16 \| Mitophagy \| Bacterial \| Autophagy \| prodrug \| VP16 \| Apoptosis \| leukemia \| Antibiotic
相关产品	Guanidine hydrochloride \| Doxycycline \| Neomycin sulfate \| Hydroxychloroquine \| Dimethyl sulfoxide \| Sulfamethoxazole sodium \| Paeonol
相关库	微生物天然产物库 \| 抗癌活性化合物库 \| 抗癌上市药物库 \| 经典已知活性库 \| 已知活性化合物库 \| 中药单体化合物库 \| 天然产物库 \| 抗癌临床化合物库 \| 抗感染天然产物库 \| 抗癌药物库

VP-16|||依托泊苷|||依托泊甙|||VP-16-213|TargetMol

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期	(12年)
注册资本	566.2651万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,试剂,定制,服务
主营行业	化学试剂,生物活性小分子